Payment overview · 2025
General Payments
$960.33
39 reported records · 14 companies
Healthcare provider profile · identity verified
Jerry Mitchell Hahn, MD
Allopathic & Osteopathic Physicians|Dermatology · ROMNEY, WV · NPI 1831181304
Verified facts
What the public records show
CMS Open Payments records show Jerry Mitchell Hahn, MD received $960.33 in general payments during 2025 across 39 reported records.
Janssen Biotech, Inc. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $173.13 | 18.0% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $132.02 | 13.8% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $115.80 | 12.1% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $102.07 | 10.6% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $100.09 | 10.4% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $92.02 | 9.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.95 | 7.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.79 | 4.5% | 2 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $33.62 | 3.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.18 | 2.4% | 1 | 2025 |
| Arcutis Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $22.29 | 2.3% | 1 | 2025 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.69 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.33 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.35 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $765.68 | 37 |
| Education | $194.65 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $159.52 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $155.20 | 3 | 2025 |
Source payment records
|
|||||
| Sotyktu Normalized: sotyktu |
Drug | E.R. Squibb & Sons, L.L.C. | $100.09 | 6 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $92.02 | 3 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $60.06 | 3 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $51.79 | 3 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $50.19 | 2 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $33.62 | 2 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| Zoryve Normalized: zoryve |
Drug | Arcutis Biotherapeutics, Inc. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| Cabtreo Normalized: cabtreo |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| JUBLIA Normalized: jublia |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| SILIQ Normalized: siliq |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| NOVACHOR Normalized: novachor |
Medical Supply | Organogenesis Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| SIMPLIMAX Normalized: simplimax |
Medical Supply | Organogenesis Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| AXERT Normalized: axert |
Drug | Janssen Biotech, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
292 | 29 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mupirocin | Mupirocin | 486 | 415 |
| Cephalexin | Cephalexin | 356 | 312 |
| Eliquis | Apixaban | 292 | 29 |
| Furosemide | Furosemide | 283 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 167 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 23 |
| Potassium Chloride | Potassium Chloride | 117 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | suppressed |
| Losartan Potassium | Losartan Potassium | 105 | 15 |
| Famotidine | Famotidine | 89 | suppressed |
| Fentanyl | Fentanyl | 89 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 16 |
| Carvedilol | Carvedilol | 72 | 11 |
| Fluorouracil | Fluorouracil | 71 | 62 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 42 |
| Tradjenta | Linagliptin | 62 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 49 |
| Donepezil Hcl | Donepezil Hcl | 59 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 15 |
| Spironolactone | Spironolactone | 59 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 56 | suppressed |
| Mirtazapine | Mirtazapine | 56 | 11 |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Lisinopril | Lisinopril | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 53 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 53 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Simvastatin | Simvastatin | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 43 | 34 |
| Buspirone Hcl | Buspirone Hcl | 41 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Prednisone | Prednisone | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Metformin Hcl | Metformin Hcl | 33 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 33 | 20 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Humira(Cf) Pen | Adalimumab | 28 | suppressed |
| Omeprazole | Omeprazole | 28 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 27 | 18 |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 16 |
| Finasteride | Finasteride | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Enbrel Sureclick | Etanercept | 22 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Restasis | Cyclosporine | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Klayesta | Nystatin | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Clozapine | Clozapine | 19 | suppressed |
| Dupixent Pen | Dupilumab | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Haloperidol | Haloperidol | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Disopyramide Phosphate | Disopyramide Phosphate | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | 12 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | 11 |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $960.33 · 39 records | Janssen Biotech, Inc. | AIRSUPRA, AXERT, Bimzelx, COSENTYX, CYGNUS DUAL, Cabtreo, DUPIXENT, EBGLYSS, JUBLIA, NEMLUVIO, NOVACHOR, Ozempic, RINVOQ, Rybelsus, SILIQ, SIMPLIMAX, SIMPONI, SIMPONI ARIA, SKYRIZI, STELARA, Sotyktu, TALTZ, TREMFYA, VIA MATRIX, Zoryve | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error